p27Kip1 and p130 Cooperate to regulate Hematopoietic Cell Proliferation in Vivo by Soeiro, Inês et al.
eCommons@AKU
Department of Pathology and Laboratory Medicine Medical College, Pakistan
August 2006
p27Kip1 and p130 Cooperate to regulate
Hematopoietic Cell Proliferation in Vivo
Inês Soeiro
Hammersmith Hospital
Azim Mohamedali
King's College London
Hanna M. Romanska
Birmingham University
Nicholas C. Lea
King's College London
Emma S. Child
Imperial College School of Medicine
See next page for additional authors
Follow this and additional works at: http://ecommons.aku.edu/
pakistan_fhs_mc_pathol_microbiol
Part of the Hematology Commons, Hemic and Lymphatic Diseases Commons, Oncology
Commons, and the Pathology Commons
Recommended Citation
Soeiro, I., Mohamedali, A., Romanska, H. M., Lea, N. C., Child, E. S., Glassford, J., Orr, S. J., Roberts, C., Naresh, K. N., Lalani, E.,
Mann, D. J., Watson, R. J., Thomas, N. B., Lam, E. -. (2006). p27Kip1 and p130 Cooperate to regulate Hematopoietic Cell Proliferation
in Vivo. Molecular and Cellular Biology, 26(16), 6170-6184.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/329
Authors
Inês Soeiro, Azim Mohamedali, Hanna M. Romanska, Nicholas C. Lea, Emma S. Child, Janet Glassford,
Stephen J. Orr, Claudia Roberts, Kikkeri N. Naresh, El-Nasir Lalani, David J. Mann, Roger J. Watson, N. Shaun
B. Thomas, and Eric W. -F. Lam
This article is available at eCommons@AKU: http://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/329
MOLECULAR AND CELLULAR BIOLOGY, Aug. 2006, p. 6170–6184 Vol. 26, No. 16
0270-7306/06/$08.000 doi:10.1128/MCB.02182-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
p27Kip1 and p130 Cooperate To Regulate Hematopoietic Cell
Proliferation In Vivo†
Ineˆs Soeiro,1 Azim Mohamedali,2 Hanna M. Romanska,3,4 Nicholas C. Lea,2 Emma S. Child,5
Janet Glassford,1 Stephen J. Orr,2 Claudia Roberts,3 Kikkeri N. Naresh,4 El-Nasir Lalani,3,4
David J. Mann,5 Roger J. Watson,6 N. Shaun B. Thomas,2 and Eric W.-F. Lam1*
Department of Oncology and Cancer Research UK Labs, MRC Cyclotron Building, Imperial College London, Hammersmith Hospital,
Du Cane Road, London W12 0NN, United Kingdom1; King’s College London, Department of Haematological Medicine,
The Rayne Institute, 123 Coldharbour Lane, London SE5 9NU, United Kingdom2; Department of Pathology,
Cancer Studies Division, Birmingham University, Birmingham B15 2TT, United Kingdom3; Department of
Histopathology, Hammersmith Hospital & Imperial College London, Du Cane Road, London W12 0HS,
United Kingdom4; Biochemistry Building, Division of Cell and Molecular Biology, Faculty of
Life Sciences, Imperial College, South Kensington, London SW7 2AZ, United Kingdom5; and
Department of Virology, Faculty of Medicine, St. Mary’s Campus, Imperial College London,
Norfolk Place, London W2 1PG, United Kingdom6
Received 10 November 2005/Returned for modification 9 December 2005/Accepted 27 May 2006
To investigate the potential functional cooperation between p27Kip1 and p130 in vivo, we generated mice
deficient for both p27Kip1 and p130. In p27Kip1/; p130/mice, the cellularity of the spleens but not the thymi
is significantly increased compared with that of their p27Kip1/ counterparts, affecting the lymphoid, ery-
throid, and myeloid compartments. In vivo cell proliferation is significantly augmented in the B and T cells,
monocytes, macrophages, and erythroid progenitors in the spleens of p27Kip1/; p130/ animals. Immuno-
precipitation and immunodepletion studies indicate that p130 can compensate for the absence of p27Kip1 in
binding to and repressing CDK2 and is the predominant CDK-inhibitor associated with the inactive CDK2 in
the p27Kip1/ splenocytes. The finding that the p27Kip1/; p130/ splenic B cells are hypersensitive to
mitogenic stimulations in vitro lends support to the concept that the hyperproliferation of splenocytes is not
a result of the influence of their microenvironment. In summary, our findings provide genetic and molecular
evidence to show that p130 is a bona fide cyclin-dependent kinase inhibitor and cooperates with p27Kip1 to
regulate hematopoietic cell proliferation in vivo.
For mammalian cells to duplicate, they have to progress
through a series of processes that comprise the cell cycle. The
retinoblastoma protein (pRB) pathway (i.e., cyclins, CDKs,
CDK-inhibitors [CKIs], pRB, and E2F) links the positive and
negative proliferative signals to the cell cycle machinery, and
this pathway is inactivated in the majority of human cancers
(37, 38). Mammalian cells become growth factor independent
after passing the restriction point within the G1 phase of the
cell cycle (34). Two families of G1 cyclins, D-type cyclins (cyclin
D1, D2, and D3) and cyclin E (cyclin E1 and E2) (37), and
their dependent kinases (CDK4, -6, and -2) control the tran-
sition through G1 into the S phase of the cell cycle. The prin-
cipal cellular targets of the G1 cyclin-dependent CDKs are the
pRB family of pocket proteins, consisting of pRB, p107, and
p130. In quiescent cells, hypophosphorylated forms of the
pRB-related pocket proteins associate with members of the
E2F family of transcription factors, thereby negatively regulat-
ing the transcriptional activity of E2F-regulated genes, whose
products are important for entry into S phase and DNA syn-
thesis (26). In their active forms, cyclin-CDK complexes hy-
perphosphorylate pRB-related pocket proteins, converting
the proteins into their inactive forms. The activities of CDKs
are negatively regulated by the CKIs, including the CIP/KIP
family of CKIs (p21Cip1/Waf1, p27Kip1, and p57Kip2) that tar-
get a broad spectrum of CDKs and the INK4 family of CKIs
(p15Ink4b, p16Ink4a, p18Ink4c, and p19Ink4d) that specifically
inhibits cyclin D-CDK4/ CDK 6 interaction (37). In addition
to their roles as CKIs, low levels of p21Cip1 and p27Kip1 also
function to promote the assembly of CDK4 (or CDK6) with
the D-type cyclins (3).
Hematopoietic cell number is maintained by the balance
between proliferation, differentiation, and death by apoptosis
(35, 39). The perturbation of this equilibrium can lead to
hematopoietic disorders, including autoimmune diseases, leu-
kemias, and other myeloproliferative and lymphoproliferative
disorders (35). Most of the hematopoietic progenitor and ma-
ture blood cells are relatively short lived, as they are constantly
eliminated by apoptosis. To compensate for this high rate of
cell loss, the hematopoietic system requires the production of
1011 human (or 108 mouse) cells each day. Besides this routine
turnover, hematopoietic cell proliferation is also required at
times of physiological stress. For example, red blood cell
numbers increase under conditions of hypoxia, while gran-
ulocyte, macrophage, and lymphocyte populations expand
during infections.
The cell cycle is under stringent control during hematopoi-
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etic cell development (14, 40). Restricting access into the cell
cycle can help preserve the hematopoietic stem cell and pro-
genitor populations from exhaustion. CKIs, including p21Cip1
and p27Kip1, are believed to set the stoichiometric thresholds
for cell cycle entry in response to mitogenic stimuli, such as
cytokines and interactions with stromal cells and the extracel-
lular matrix. p21Cip1 and p27Kip1 have been shown to maintain
the quiescence of hematopoietic stem cells and progenitor
cells, respectively, thereby governing their pool sizes (4, 5). In
addition, p27Kip1 has been demonstrated to negatively regulate
the cell cycle entry of some of the more mature hematopoietic
cells. However, recent mouse gene deletion studies show that,
despite a pronounced lymphoid hyperplasia in thymus and
spleen, p27Kip1/ mice do not display overt hematopoietic
proliferative abnormalities, indicating that other negative reg-
ulators must become activated to compensate for and to main-
tain hemopoietic cell numbers. Nevertheless, it is unlikely that
the function of p27Kip1 is substituted by the structurally related
Cip/Kip-family of CKIs, as p57Kip2 is not normally expressed at
significant levels in most hematopoietic cells (29) and recent
work with p21Cip1-null mice suggested that p21Cip1 does not
have a role in controlling the proliferation of hematopoietic
progenitors and more mature blood cells (4, 5).
A recent study proposed that p130 can function as a CDK2
inhibitor and can compensate for the loss of p27Kip1 in p27Kip1-
null murine embryonic fibroblasts (MEFs) to inhibit CDK2
activity (8, 10). In MEFs with both p27Kip1 and p130 deleted,
cyclin E-Cdk2 kinase activity cannot be inhibited by mitogen
starvation in vitro. It is therefore possible that the lack of overt
hematopoietic proliferative disorders in the p27Kip1/ mice is
due to functional compensation by the pRB-related p130 pro-
tein. However, there have been no data available to suggest
that this compensatory mechanism occurs in vivo. To investi-
gate this possibility, we crossbred the mice with p27Kip1 and
p130 deleted to generate mice deficient for both p27Kip1 and
p130 in order to study whether the proteins have overlapping
roles in proliferative control. Since previous data from an
analysis of p27Kip1/ mice showed that p27Kip1 is a specific
proliferative regulator for hematopoietic organs, including
thymus and spleen (15, 23, 32), we therefore focused our
study on the effects of this p27Kip1 and p130 double deletion
in these hematopoietic organs, where p27Kip1 has a distinct
antiproliferative role.
MATERIALS AND METHODS
Mice breeding and genotyping. The p130/ and p27Kip1/ singly deficient
mice have been described previously (9, 15) and were kindly provided by Jim M.
Roberts (Howard Hughes Medical Institute, Seattle, WA) and Nicholas J. Dyson
(Massachusetts General Hospital Cancer Research Center, Boston, MA). These
mice were backcrossed into the C57BL/6 background for two generations and
housed at the Imperial College’s animal facilities. Double-knockout (DKO)
mice, generated by interbreeding p130/ and p27Kip1/ animals, were main-
tained with the single-knockout mice and the wild-type (WT) controls in the
same background within the same colony. Initial crosses of the single-mutant
mice yielded p27Kip1/; p130/ animals, which were subsequently intercrossed
for a number of generations to eventually generate the breeding pairs consisting
of p27Kip1/; p130/ male and p27Kip1/; p130/ female animals. We had to
use p27Kip1/; p130/ female mice for breeding, as the female animals with
p27Kip1 homozygous deletions are sterile (15, 23, 32). All mice were used at 8 to
12 weeks of age unless specified otherwise. The genotypes of the mice were
determined by PCR using genomic DNA extracted from tail biopsy specimens.
The genomic DNA was obtained using the QIAGEN DNeasy tissue kit according
to the manufacturer’s instructions. The PCR primers are as follows: p27Kip1-
mutant sense, 5-TGG AAC CCT GTG CCA TCT CTA T-3; mutant antisense,
5-CCT TCT ATC GCC TTC TTG ACG-3; wild-type sense, 5-GAT GGA
CGC CAG ACA AGC-3; wild-type antisense, 5-CTC CTG CCA TTC GTA
TCT GC-3; p130 common, 5-ACG GAT GTC AGT GTC ACG-3; wild type,
5-TAC ATG GTT TCC TTC AGC GG-3; and mutant, 5-GAA GAA CGA
GAT CAG CAG-3. All PCRs were carried out in the presence of 2.5 mM MgCl2
at 55°C. Analysis of the PCR products was performed on a standard 2% (wt/vol)
agarose gel.
Hematopoietic cell isolation and staining. Mice were sacrificed, and their bone
marrow, spleens, and thymi were removed. From these hematopoietic organs,
single-cell suspensions were prepared in RPMI 1640 medium by pipetting and
then passing through a 70-m nylon mesh. Cells were washed in phosphate-
buffered saline (PBS) containing 0.2% bovine serum albumin, and an aliquot was
taken for cell counting in a trypan blue (Sigma, Poole, United Kingdom) exclu-
sion assay. Cells were pelleted by centrifugation for the preparation of whole-cell
extracts. For the isolation of lineage-specific hematopoietic cells, cells were
sequentially incubated with Miltenyi immunomagnetic microbeads specific for
B220 (B cells), Gr1 (monocytes plus macrophages), or Ter-119 (erythroid cells).
CD3-positive cells (T cells) were initially stained for 15 min with CD3-fluorescein
isothiocyanate (FITC) as described above, followed by staining with anti-FITC
immunomagnetic microbeads. Different lineages captured with the microbeads
were isolated using the AutoMACS cell sorter (Miltenyi Biotec Ltd., Surrey,
United Kingdom) in a two-column purification program specified by the manu-
facturer. Half of the positive fraction was stained using the appropriate antibody
to test for hematopoietic lineage purity, and the other half was fixed for cell cycle
analysis. In general, the purity of the lineage-specific cells obtained was 90%,
as verified by flow cytometric analysis. For the quantification of lineage-specific
hematopoietic cells, nucleated cells from spleens were labeled with lineage-
specific antibodies (CD3, B220/CD45R, Gr-1, and Ter-119). The purified mono-
clonal antibodies anti-CD3ε, phycoerythrin (PE)- or FITC-conjugated anti-B220,
PE-conjugated Ter-119, and FITC-conjugated anti-Ly-6G (Gr-1) as well as the
respective isotype controls were obtained from BD Pharmingen (Cowley, United
Kingdom).
Histological studies and immunohistochemical staining. Following fixation in
10% phosphate-buffered formalin, tissue blocks were dehydrated in graded al-
cohol by using standard histological techniques, embedded in paraffin, and sec-
tioned with a microtome. Sections were cut for immunohistochemistry onto
Snowcoat Xtra slides (Surgipath, Peterborough, United Kingdom). The histo-
logical appearance was observed following counterstaining with hematoxylin and
eosin (H&E) (Sigma, United Kingdom). Paraffin sections (5 m) mounted on
positively charged glass slides (VWR International, United Kingdom) were pro-
cessed for conventional histology (H&E) and immunocytochemistry using the
avidin-biotin-peroxidase complex (ABC) method (19). Immunocytochemistry for
CD3 (rabbit anti-human polyclonal antibody, diluted 1:1,500; Dako, United
Kingdom), CD45R/B220 (biotin-conjugated rat anti-mouse monoclonal anti-
body, diluted 1:1,000; BD Biosciences, United Kingdom), Ter-119 (rat anti-
mouse monoclonal antibody, diluted 1:20; BD Pharmingen, United Kingdom),
and Gr1 (rat anti-mouse monoclonal antibody, diluted 1:10; eBioscience, United
Kingdom) was carried out after antigen retrieval by autoclaving sections at 126°C
for 20 min according to the method of Banktlavi and coworkers (1). In brief,
following autoclaving, the sections were immersed for 30 min in PBS containing
fresh 0.3% (vol/vol) hydrogen peroxide, rinsed in PBS for another 30 min, and
incubated for 10 min in normal goat (for CD3) or rabbit (for B220, Ter-119, and
Gr1) serum diluted 1:20 in PBS. An incubation with primary antibodies was
carried out overnight in a humid chamber at 4°C. The second layer of biotinyl-
ated goat anti-rabbit (for CD3) or anti-rat (for Ter-119 and Gr1) serum (1:200;
Vector Labs Ltd., Peterborough, United Kingdom) and the third layer of ABC
complex (Vector ABC reagent, diluted 1:100) were each applied for 30 min at
room temperature. Thorough rinsing in PBS (three 5-min washes) was applied
between the sequential steps of the procedure. After a final rinsing in PBS, the
sections were developed and counterstained with hematoxylin. Microscopic im-
ages were captured using an Olympus DP70 camera (Shinjuku-ku, Tokyo, Ja-
pan). As a negative control for the immunostaining, nonimmune serum was used
as a first layer.
B-cell isolation and culture. Splenic B cells were prepared by previously
published methods (22). Briefly, T cells were killed by a cocktail of monoclonal
antibodies against Thy-1, CD4, and CD8 plus guinea pig complement (25).
Small, dense B cells were then isolated on Percoll density gradients, and eryth-
rocytes were depleted by treatment with a lysis solution consisting of 0.15 M
NH4Cl. These preparations typically consisted of95% B lymphocytes. The cells
were cultured at 105 cells per 100 l in RPMI 1640 medium supplemented with
5% fetal calf serum, 2 mM glutamine, 100 U/ml penicillin-streptomycin, and 50
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M 2-mercaptoethanol and stimulated with either 10 g/ml of polyclonal anti-
immunoglobulin M (IgM) [affinity-purified F(ab)2 goat anti-mouse IgM (Cap-
pel-ICN, Costa Mesa, CA)] or lipopolysaccharide (LPS) (Escherichia coli sero-
type O55:B5; Sigma, Poole, United Kingdom), 100 U/ml interleukin-4 (IL-4)
(R&D Systems, Abingdon, United Kingdom), 10 g/ml anti-CD40 (clone 3/23)
(25), IL-4 plus anti-IgM, anti-CD40 plus anti-IgM, or IL-4 plus anti-CD40. Cells
were collected at times indicated for poststimulation.
Cell cycle analysis. Cell cycle analyses were performed by combined pro-
pidium iodide (PI) (Sigma) and FITC (Sigma) staining as described previously
(43). Briefly, cells were washed with PBS and fixed in 90% ethanol-10% PBS.
Following fixation, cells were washed again and then incubated with 50 g ml1
DNase-free RNase (Sigma), 50 g ml1 PI, and 0.1 g ml1 FITC for 30 min at
37 C prior to analysis using a FACSCalibur flow cytometer (Becton Dickinson,
Cowley, United Kingdom).
Western blot analysis and antibodies. Western blot whole-cell extracts were
prepared by lysing cells with four times the packed cell volume of lysis buffer (1%
Nonidet P-40, 100 mM NaCl, 20 mM Tris [pH 7.4], 10 mM NaF, 1 mM sodium
orthovanadate, and protease inhibitors (Complete; Roche, Welwyn Garden City,
United Kingdom) on ice for 15 min. The protein yield was quantified by using a
DC protein assay kit (Bio-Rad, Hemel Hempstead, United Kingdom). A total of
50 g of lysate was separated by sodium dodecyl sulfate (SDS)-polyacrylamide
gel electrophoresis, transferred to nitrocellulose membranes and recognized by
specific antibodies. The antibodies against cyclin D2 (M-20), cyclin D3 (18B6-
10), cyclin E (M-20), CDK2 (M2), CDK4 (C-22), CDK6 (C-21), p27Kip1 (C-19),
p107 (C-18), and pRB (C-15) were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). The anti-phospho pRB (Ser807/811) antibody was purchased
from Cell Signaling Technologies (Hitchin, United Kingdom), and the anti-
phospho pRB (Thr821) antibody was from Biosource International (Camarillo,
CA). The anti-p130 (anti-pRB2) (K25020) monoclonal antibodies were acquired
from Transduction Laboratories (Cambridge, United Kingdom). The antibodies
were detected by using horseradish peroxidase-linked goat anti-mouse or anti-
rabbit IgG (Dako, Ely, United Kingdom) or mouse-absorbed goat anti-rat IgG
(Southern Biotechnology Associates, Inc.) and visualized by an enhanced chemi-
luminescence detection system (Amersham Pharmacia Biotech, Amersham,
United Kingdom).
Immunoprecipitation, CDK kinase assays, and immunodepletion. For the
immunoprecipitation and CDK kinase assays, the cells collected were washed
with PBS and lysed in lysis buffer containing 20 mM Tris-HCl (pH 7.9), 150 mM
NaCl, 1 mM EGTA, 1 mM EDTA (pH 8.0), 1% Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluo-
ride. Protein lysates (100 g) were then incubated with 5 g of anti-CDK2 (M-2)
for 2 h at 4°C. At 2 h, 50% protein A-Sepharose beads (20 l; Amersham
Pharmacia Biotech) in lysis buffer were added and the mixture was incubated for
an additional 2 h. The anti-CDK2 immunoprecipitates were then washed sub-
stantially and resuspended in 20 l of kinase buffer (20 mM Tris-HCl [pH 8.0],
10 mM MgCl2, 1 mM EDTA, 1 mM dithiothreitol) supplemented with 2.5 g of
recombinant pRB protein and 10 Ci of [-32P]ATP (3,000 Ci/mmol; Amersham
Pharmacia Biotech). Reaction mixtures were incubated for 15 min at room
temperature, and the phosphorylated recombinant pRB protein was resolved
with 10% SDS-polyacrylamide gel electrophoresis. The gels were then dried and
exposed to X-ray films. From isolated B220 and CD3 cells, immunoprecipi-
tation kinase assays were performed as described previously (21), except that
cells were lysed in 20 mM Tris-HCl (pH 8.0), 250 mM NaCl, 0.5% NP-40, and 1
mM EDTA. For immunodepletion experiments, two extra immunoprecipitations
were performed with either the anti-p27Kip1 antibody (C-19) or the p130 anti-
body. The resultant supernatants were resolved on an SDS-polyacrylamide gel
electrophoresis gel and analyzed by Western blotting.
[3H]thymidine incorporation assays. Cell proliferation was monitored by
[3H]thymidine incorporation assays. Small dense splenic B cells were seeded into
96-well plates at 105 cells per well and cultured in 200 l of RPMI, 0.5 Ci
[3H]thymidine, and 10% fetal calf serum. [3H]thymidine was added for the final
4 h of the indicated culture times. Cells were collected using a PHD cell harvester
(Cambridge Technology, Cambridge, MA), and [3H]-thymidine incorporation
into DNA was quantified by scintillation counting. Each point was determined in
quadruplicate, and each growth curve was performed at least three times.
RESULTS
Increase in cell cycle entry and cell number of p27Kip1/;
p130/ splenocytes. At all stages of interbreeding, the birth of
offspring generally obeyed the Mendelian ratio, with the out-
comes not statistically different from the predicted values (see
Fig. S1 in the supplemental material). However, it was notable
that there was a small and nonsignificant (P  0.066) bias
against the p130/ genotype when we initially crossed p130
heterozygous mice after one generation of backcrossing into a
C57BL/6 background. Nevertheless, most of our later crosses
using mice after two generations of backcrossing into C57BL/6
showed that births obey the predicted Mendelian ratios. The
reason for this bias is unclear, but it could be due to the fact
that p130 knockouts in some backgrounds, including BALB/c,
are embryonic lethal (28). As a result, mice having had two
generations of backcrossing will have an enriched C57BL/6
background, which has been shown to protect offspring from
the lethal effects of p130 deletion (28). Our breeding also
showed that p27Kip1/; p130/ mice are viable, but there was
an apparent higher mortality rate among p27Kip1/; p130/
mice (8.7%; 26 deaths among 298 mice within the first 9
months) compared with those of their p27Kip1/ (2.5%;
4/120), p130/ (4.4%; 3/68), and wild-type (2.5%; 3/132)
counterparts; however, the causes of the deaths were unknown.
Like p27Kip1/ animals, p27Kip1/; p130/ mice have higher
body weights than wild-type and p130/ mice of the same
ages (see Fig. 2B). Nevertheless, there is no significant differ-
ence in body weight between p27Kip1/ and p27Kip1/;
p130/ mice. As reported, the p130/ mice develop nor-
mally and have body weights similar to those of wild-type mice.
Consistent with previous reports, the p27Kip1/ mice display
organomegaly and infertility and these phenotypes are re-
tained in p27Kip1/; p130/ mice.
To investigate the effects of p27Kip1 and/or p130 deletion on
the proliferation of hematopoietic cell populations, we first
studied the cell cycle distribution of nucleated cells isolated
directly from the thymus and spleen of the wild-type as well as
the singly and doubly deficient mice (Fig. 1A). To this end,
cells prepared from these hematopoietic organs were analyzed
by flow cytometry following propidium iodide and FITC stain-
ing (17, 25). The results showed that the cell cycle profiles of
cells from both the spleen and thymus of p130/ mice are
similar to those of their wild-type counterparts. However, there
were marginal increases in S- and G2/M-phase cells in the
thymus and the spleen of p27Kip1/ mice. Even higher per-
centages of S and G2/M cells were observed in the p27
Kip1/;
p130/ animals, with the increase more obvious in the spleen
than in the thymus (Fig. 1B). Despite the large error range for
the S- and G2/M-phase splenic cells in the p27
Kip1/; p130/
animals, the difference between p27Kip1/ and p27Kip1/;
p130/ groups is significant (t test; P  0.01). These results
suggested that both p27Kip1 and p130 function in the same
proliferation regulatory pathway and that p130 compensates
for the absence of p27Kip1 in the spleen of the p27Kip1-null
mice to negatively control cell cycle entry.
The spleens from the p27Kip1/; p130/ animals were
larger (Fig. 2A) and heavier (Fig. 2B) and had averages of five
and three times more cells than those from wild-type
(p130/) and p27Kip1/ animals, respectively (Fig. 2C). Both
of the single-knockout mice also harbored spleens that were
larger, with a higher number of cells than those of the wild-
type, but to a lesser extent than did the double-knockout mice.
This evidence confirms previous reports (15, 23, 32) that stated
that the p27Kip1-null mice exhibited higher cellularity than
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wild-type mice in several hematopoietic organs, including the
spleen and thymus.
Sections from spleen and thymus were studied from four sets
of mice (wild-type, p27Kip1/, p130/, and p27Kip1/;
p130/) (Fig. 3). There were no significant differences in
thymus upon morphological evaluation (data not shown).
Compared to other groups, spleens from p27Kip1/; p130/
showed expanded red pulp containing predominantly erythroid
and myeloid compartments. The red pulp-to-white pulp (con-
sisting of primarily lymphoid cells) ratio among the p27Kip1/;
p130/ group was more than 1.5, while among the other
groups it was less than 0.75. Furthermore, the density of nu-
cleated cells in the red pulp was four to five times higher in the
p27Kip1/; p130/ group than in the wild type. Among
p27Kip1/ and p130/ mice, the cell density in the red pulp
was 1.5 to 3 times that of the wild type. The expanded red pulp
of the p27Kip1/; p130/ mice showed trilineage hematopoi-
esis in the form of groups of nucleated erythroid cells, matur-
ing myeloid precursors, and occasional megakaryocytes. Al-
though this was best appreciated in the p27Kip1/; p130/
mice, mice from other groups also had trilineage hematopoi-
esis, but this was of a lesser volume and proportion.
To identify the cell populations responsible for this spleen
hyperplasia in the p27Kip1- and p130-deficient mice, we used
microbeads to separate the T and B lymphocytes, the granu-
locytes plus monocytes, and the erythroid cells from 8- to
9-week-old mice and analyzed their respective cell cycle sta-
tuses (SG2/M percent) by staining with propidium iodide
FIG. 1. Cell-cycle analysis of hematopoietic cells from wild-type, p27Kip1/, p130/, or p27Kip1/; p130/ mice. Nucleated splenic or thymic
cells from WT, p27Kip1/, p130/, or p27Kip1/; p130/ DKO mice were permeabilized and stained with PI and FITC to measure DNA (x axis)
and protein (y axis) content, respectively, and measured by flow cytometry. (A) A representative cell cycle analysis in which the percentage of cells
in each phase of the cell cycle (sub-G1 [G1], G0/G1, S, and G2/M), determined by their DNA and protein contents, are indicated. (B) The total
percentage of cells in S and G2/M phase of different types of mice is shown in the histogram (mean 	 standard deviation [SD]; n  12). Student
t tests were performed between the DKO samples and the WT, p27Kip1/, or p130/ samples. There is a statistically significant difference
between the DKO group and the other genotypes (P  0.01) in the spleen but not the thymus.
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(Fig. 4A and B). Younger mice of a narrower age range were
used because of the detection of splenomegaly in older mice
and the huge error range of the previous whole-spleen cell
cycle experiment (Fig. 1B). In these experiments, we observed
an increase in the SG2/M percent in all cell types examined,
but a particularly higher level of SG2/M cells was detected in
the Ter-119 erythroid population (33) and the Gr1 popula-
tion containing granulocytes plus monocytes (31, 46). Consis-
tent with this, we also detected a significant increase in cell
number in all splenic cell types, but the increases in the Ter-
119 and Gr1 cell populations were again the most dramatic
(Fig. 4C).
An increase in B220, CD3, Ter-119, and Gr1 cells in
the spleens of p27Kip1- and p130-deficient animals. To confirm
that there was an increase in all of the major hemopoietic cell
types in the spleens of p27Kip1- and p130-deficient animals, we
performed immunohistochemical staining of spleen sections
from four sets of mice (wild type, p27Kip1/, p130/, and
p27Kip1/; p130/) with specific antibodies against B220/
CD45R, CD3, Ter-119, and Gr1 (Fig. 5). The results confirmed
the earlier H&E staining results and showed that there was an
increase in cell numbers of all major hemopoietic cell types (B
and T cells, erythroid cells, monocytes, and macrophages) in
the spleens of the p27Kip1/; p130/ mice compared with
FIG. 2. Comparisons of spleen sizes and cellularities between wild-type, p27Kip1/, p130/, and p27Kip1/; p130/ mice. (A) Representative
photograph images of spleens from wild-type, p27Kip1/, p130/, and p27Kip1/; p130/ mice. (B) Histograms showing the average body weights
(left panel) and spleen weight/body weight ratios (right panel) from wild-type, p27Kip1/, p130/ and p27Kip1/; p130/ mice (mean 	 SD
[error bars]; n  6) (left panel). Student t tests were performed between the DKO group and the WT, p27Kip1/, or p130/ group. There is a
statistically significant difference in average body weights between the DKO group and the WT or p130/ groups (P 0.01) but not the p27Kip1/
group. (C) Histograms showing the average total cell numbers of splenocytes and thymocytes present in wild-type, p27Kip1/, p130/, and
p27Kip1/; p130/ mice (mean 	 SD [error bars]; n  6). The individual cell numbers are shown by circles alongside the histograms. There is
a statistically significant difference between the DKO group and the other genotypes (P  0.01) in the spleen but not the thymus.
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their wild-type, p27Kip1/, and p130/ counterparts. In the
spleens of wild-type mice, the B220/CD45R B lineage cells
were closely packed in the outer region of the white pulps
(lymphoid sheaths). In the spleens of p27Kip1/, p130/, and
p27Kip1/; p130/ mice, the B cells were densely packed
towards the inner region, with the highest increase in B-cell
number and density observed in the spleens of p27Kip1/;
p130/ mice. The CD3 T cells were located predominantly
around the central arterioles in the wild-type and spleens of
p130/ mice. The distribution of the CD3 T cells in spleens
of p27Kip1/ mice was similar to those in the spleens of wild-
type and p130/ mice but had increased density. The density
of the CD3 T cells further increased in the spleens of
p27Kip1/; p130/ mice, and the p27Kip1/; p130/ splenic
T cells were located predominantly towards the central region
of the lymphoid sheaths. In the spleens of p27Kip1/, p130/,
and wild-type mice, the Ter-119 cells were observed primarily
in the peripheral region (lymphoid sheaths) and were of sim-
ilar densities. The Ter-119 cells in the spleens of p27Kip1/;
p130/ mice were again of a distribution similar to those the
other genotypes but were of a much higher density. The im-
munoreactivity of the Gr1 antibody was weak, which is likely to
be due to tissue processing; however, the results also demon-
strated that the Gr1 cells had higher densities and cell num-
bers in the red pulps of the spleens of p27Kip1/; p130/
mice.
Expression of cell cycle regulators in p27Kip1- and/or p130-
deficient spleens and thymus. The fact that all of the major cell
types in the spleens of p27Kip1/; p130/ mice displayed
increased cell cycle entry allowed us to investigate the molec-
ular mechanism responsible for this hyperproliferative effect by
analyzing unfractionated splenocytes. We took advantage of
this and examined the expression of cell cycle regulators by
Western blot analysis (Fig. 6A). Although most cell cycle reg-
ulatory proteins were present at comparable levels in the thy-
mus and the spleen, there was also some variation between
FIG. 3. Hematoxylin and eosin-stained sections of spleens of wild-type, p27Kip1/, p130/, and p27Kip1/; p130/ mice. Spleen sections from
WT, p27Kip1/, p130/, and p27Kip1/; p130/ DKO mice were stained with H&E. Representative sections were shown (n  6 for each
genotype). Mice genotypes and magnifications (
40,
100,
250, and
500) are indicated. Spleen sections from p27Kip1/; p130/ mice showed
an expanded red pulp. The splenic red pulp of p27Kip1/; p130/ mice showed a high cell density. Trilineage hematopoiesis (indicated by arrows)
in the form of groups of nucleated erythroid cells, maturing myeloid precursors, and occasional megakaryocytes (indicated by an asterisk) are
noted. This is best appreciated in the splenic sections from the p27Kip1/; p130/ mice. Scale bars with widths are shown.
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these two organs. The splenocytes expressed a lower level of
CDK6, CDK2, and p107 and a higher level of cyclin D2 com-
pared with the thymocytes. In the spleen, cyclin D2 expression
was down-regulated in both the p27Kip1/ and the p27Kip1/;
p130/ samples, suggesting a positive role of p27Kip1 in cyclin
D2 expression. In the spleen of the double-knockout mice,
there was also an increase in the expression of p107 and cyclin
E and A proteins, which are E2F-regulated gene products and
known regulators of the G1/S and S phases. Since cyclin E and
A accumulation is important for passage through the G1 and S
phases, the higher levels of cyclin E and A expression in dou-
ble-knockout splenocytes compared with that in the wild-type
and single-knockout cells explains the greater levels of cell
cycle entry and DNA synthesis observed. Since T821 is a
CDK2-specific phosphorylation site on pRB and other studies
have used T821 pRB phosphorylation as a surrogate for CDK2
activity (27, 45), we therefore used the anti-pRB (T821) phos-
phospecific antibody to gauge the CDK2 activity. The result
showed an increase in CDK2-dependent pRB phosphorylation
in the double-knockout splenocytes, indicating an increase in
CDK2 activity. The results of Western blot analysis supported
the hypothesis that p130 compensates for the loss of p27Kip1 in
p27Kip1/ cells to inhibit CDK2 activity. The data also indi-
cated that this compensatory mechanism is specific for spleno-
FIG. 4. Cell cycle analysis and cellularity of lineage-specific splenocytes. Nucleated splenocytes were harvested from wild-type, p27Kip1/,
p130/, and p27Kip1/; p130/ mice and sorted according to cell surface markers using immunomagnetic microbeads against B220 (B cells),
CD3 (T cells), Gr1 (monocytes plus macrophages), and Ter-119 (erythroid progenitors). These cells were then analyzed for their cell cycle
distributions as previously described in the legend for Fig. 1. (A) Representative cell cycle analysis in which the percentage of lineage-specific
splenocytes in each phase of the cell cycle (sub-G1 [G1], G0/G1, S, and G2/M), as determined by their DNA and protein contents, are indicated.
(B) The total percentage of lineage-specific cells in the S and G2/M phases of different types of 8- to 9-week-old mice is shown in the histogram
(mean 	 SD [error bars]; n  6). Student t tests were performed between the DKO group and the WT, p27Kip1/, or p130/ group. There is
a statistically significant difference between the DKO group and the other genotypes (P  0.01). (C) Histograms showing the average cell numbers
of lineage-specific splenocytes present in wild-type, p27Kip1/, p130/, and p27Kip1/; p130/ mice (mean 	 SD [error bars]; n  6). The
individual cell numbers are shown by circles alongside the histograms. Student t tests were performed between the DKO group and the WT,
p27Kip1/, or p130/ group. There is a statistically significant difference between the DKO group and the other genotypes (P  0.01).
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cytes, as the induction in CDK2-dependent activity is detected
in only splenocytes, not thymic cells and bone marrow cells
(data not shown).
CDK2 activity is up-regulated in the p27Kip1 and p130 dou-
bly-deficient splenocytes. We next performed immunoprecipi-
tation kinase experiments to confirm the observation that
CDK2 activity is up-regulated in the p27Kip1 and p130 doubly
deficient splenocytes. CDKs were immunoprecipitated from
these cells, and the associated kinase activity was measured
using a bacterially expressed glutathione S-transferase–pRB as
a substrate (Fig. 6B). We found that the immunoprecipitated
CDK2 but not CDK4 or CDK6 activity is significantly up-
regulated (catalytically active) in the p27Kip1 and p130 doubly
deficient splenocytes but not in their wild-type, p27Kip1/, and
p130/ counterparts. The data also indicated that CDK2 ac-
tivity is at a basal level in the splenocytes of p27Kip1/ mice, as
in the wild-type splenic cells, and this activity is increased
through further deletion of p130, suggesting that p130 com-
pensates for the absence of p27Kip1 in the spleen cells of
p27Kip1/ mice to inhibit CDK2 activity. Interestingly, this
induction in CDK2 activity was not observed in the p27Kip1/;
p130/ cells isolated from the thymus, again indicating that
this compensatory mechanism by which CDK2 is inhibited is
tissue and cell type specific. These results are in agreement
FIG. 4—Continued.
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with our observations with the phosphospecific pRB anti-
bodies.
An increase in CDK2 activity in the splenic B220, CD3,
Ter-119, and Gr1 cells of p27Kip1- and p130-deficient mice.
To investigate the hematopoietic cell type(s) that contributed
to the increase in CDK2 activity in the spleens of the
p27Kip1/; p130/ mice, we purified Ter-119, B220,
CD3, and Gr1 cells from the four splenic lineages and
studied the CDK2 activity by Western blot analysis using anti-
phospho-pRB T821 antibodies and by immunoprecipitation
kinase assays. Western blot analysis demonstrated that the
CDK2 activity was up-regulated in the cells of p27Kip1/;
p130/ mice of all four hematopoietic lineages (Ter-119,
B220, CD3, and Gr1) compared with that in the cells of
p27Kip1/, p130/ and wild-type mice (Fig. 7A). The results
also showed that, in general, key cell cycle regulators, including
p130, pRB, p27Kip1, and CDK2, in these four cell lineages were
expressed in a pattern similar to that of the total splenic ly-
sates. Immunoprecipitation kinase experiments performed
with the B220, CD3, and Tre-119 cells showed that, in
these three cell lineages, the CDK2-associated kinase activity
was up-regulated in the cells of p27Kip1/; p130/ mice com-
pared with that in their p27Kip1/, p130/ and wild-type
counterparts (Fig. 7B). However, we failed to perform success-
ful immunoprecipitation kinase studies with Gr1 cells, and
this was most likely due to the limited numbers of cells puri-
fied. Nevertheless, together, the Western blotting and immu-
noprecipitation kinase results clearly indicated that the CDK2
activity is elevated in the cells of p27Kip1/; p130/ mice in
all four hematopoietic cell lineages and supported the notion
that p27Kip1 and p130 cooperate to repress CDK2 activity in
these cells.
CDK2 is associated with p130 in the p27Kip1-null cells and
vice versa. To investigate the compensatory mechanism that
represses the CDK2 activity in the p27Kip1- and/or p130-defi-
cient cells, we then immunoprecipitated CDK2 from spleno-
cytes and thymocytes and analyzed the associated CKI by
Western blotting (Fig. 8). The experiments showed that
p27Kip1 associated with the CDK2 complexes in both wild-type
and p130/ cells (Fig. 8A). However, in the wild-type cells, a
FIG. 5. Sections of wild-type, p27Kip1/, p130/, and p27Kip1/; p130/ spleens stained with antibodies against B220/CD45R, CD3, Ter-119,
and Gr1. Spleen sections from WT, p27Kip1/, p130/, and p27Kip1/; p130/ DKO mice were stained with specific antibodies against B220
(B cells), CD3 (T cells), Ter-119 (erythroid progenitors), and Gr1 (monocytes plus macrophages). Representative sections (magnification, 
250)
are shown (n  6 for each genotypes stained). Mice genotypes and the antibodies used are indicated. The spleens of p27Kip1/; p130/ mice
showed increased cell densities and numbers in all four cell lineages studied, consistent with earlier H&E staining (Fig. 3). Scale bars, 40 m.
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small amount of p130 also bound to CDK2 and the levels of
p130 interacting with CDK2 increased when p27Kip1 was de-
leted. We also analyzed whether p27Kip1 or p130 was also
detected in CDK4 and CDK6 complexes but failed to detect
significant levels of p27Kip1 or p130 interacting with either
CDK4 or CDK6 (Fig. 8B and C). The fact that there was no
induction of CDK2 activity in the thymic cell samples
prompted us to investigate whether CDK2 also associates with
the other pRB-related protein, p107, which has been shown to
be able to bind to and inhibit CDK2 kinase complexes (Fig.
8A). The results showed that CDK2 binds to p107 in both the
splenic and thymic lysates, suggesting that p107 is also involved
in the regulation of CDK2. Notably, there was an increase in
p107 interacting with CDK2 in cells with p27Kip1 deleted. This
indicates that like p130, p107 may also compensate for the
absence of p27Kip1 to modulate CDK2 activity.
To further confirm these results, we next determined the
amount of CDK2 binding to p27Kip1 and p130 by Western
blotting following immunoprecipitation (Fig. 8D and E). The
results showed that, in all wild-type cells, CDK2 binds primar-
ily to p27Kip1 and also to a low level of p130, while in all
p27Kip1/ cell types, the majority of CDK2 binds to p130. In
the absence of p130, the CDK2 complexes were associated
with p27Kip1 and, as predicted, no CDK2 was coimmunopre-
cipitated with antibodies against p27Kip1 and p130 in the dou-
bly deficient cells. The differences in the relative signals ob-
tained for p27Kip1, p130, or p107 that coprecipitates with
CDK2 in spleen relative to thymus in the above-described
experiments is explained by the fact that there is less CDK2 in
splenocytes. Taken together, these results demonstrate that
p27Kip1 and p130 each have a role in inhibiting CDK2 activity,
and there is an increase in p130 binding to CDK2 in p27Kip1/
cells compared to that in wild-type cells.
p130 is the CKI binding to CDK2 in splenocytes of
p27Kip1/ mice. While p130 is the major CKI binding to
CDK2 in the splenocytes of p27Kip1/ mice, the experiments
described did not address the scenario that another CKI could
have a more predominant role in binding to and inhibiting
CDK2 in the p27Kip1/ splenocytes. To investigate this pos-
sibility, we performed immunodepletion experiments through
serial immunoprecipitation of cell lysates with antibodies
against either p27Kip1 or p130 (Fig. 9). Three rounds of immu-
noprecipitation with either the p27Kip1 or p130 antibodies
completely eliminated CDK2 from the splenocyte lysates. The
results also demonstrated that the immunodepletion of p27Kip1
from splenocyte lysates of wild-type and p130/ mice con-
comitantly removed almost all of the CDK2, whereas the
CDK2 complexes in the lysates of p27Kip1/ and p27Kip1/;
p130/ mice were unaffected (Fig. 9A). p130 immunodeple-
tion caused a significant reduction of CDK2 protein from the
lysates of p27Kip1/ mice but had little effect on the CDK2
proteins in lysates from wild-type, p130/, and double-mutant
mice (Fig. 9B). Thus, p27Kip1 is the major CKI binding to
CDK2 in the splenic cells of wild-type and p130/ mice,
whereas p130 is the predominant CKI associated with CDK2 in
splenocytes without p27Kip1. This result is consistent with the
fact that p27Kip1 and p130 compensate for each other to reg-
ulate CDK2 activity in splenic cells. It was also notable that,
after the immunodepletion of p27Kip1 and p130, a significant
amount of CDK2 was retained in thymus cell lysates, suggest-
ing that only a fraction of the CDK2 complexes was associated
with p130 and p27Kip1. It is also possible, though unlikely, that
most of the CDK2 is not associated with a cyclin; however,
without the cyclin regulatory subunit, this pool of CDK2 will be
in an inactive form and will not be a target of CDK inhibitors.
p27Kip1/; p130/ splenic B lymphocytes have increased
proliferative rates and abilities to enter the cell cycle ex vivo.
It is possible that the increase in cellularity was due to indirect
effects from their p130- and p27-null microenvironments in the
spleen rather than the deletion of p130 and p27 in these he-
FIG. 6. Expression of cell-cycle regulatory proteins and kinase analy-
sis of CDK2, CDK4, CDK6 in the nucleated splenocytes and thymocytes
of wild-type, p27Kip1/, p130/, and p27Kip1/; p130/ mice. Nucle-
ated splenocytes and thymocytes were harvested from wild-type,
p27Kip1/, p130/ and p27Kip1/; p130/ mice. (A) Lysates (30 g)
prepared from total nucleated splenocytes or thymocytes were used for
Western blot analysis for cell cycle regulatory proteins, including cyclin D2
and D3, cyclin E and A, CDK2, -4, and -6, p27Kip1, p21Cip1, pRB, p107,
and p130. The activity of cyclin-CDK2 was determined using phosphospe-
cific anti-pRB antibodies raised against CDK2-specific sites. Actin was
used as a loading control. (B) Thymic and splenic cell lysates of wild-type
and knockout mice were immunoprecipitated (IP) with antibodies against
CDK2, CDK4, and CDK6. The immunoprecipitated CDK2, CDK4, and
CDK6 complexes were analyzed for cyclin-dependent kinase activity in an
in vitro kinase assay using recombinant pRB as a substrate. The 32P-
labeled pRB was then separated by gel electrophoresis and analyzed by
exposure to autoradiographic film.
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mopoietic cells. To investigate this possibility, we isolated
small, dense (resting) B cells from the double- and single-
knockout mice and monitored their proliferative rates ex vivo
by [3H]thymidine incorporation in response to mitogenic stim-
ulations (Fig. 10). The B cells from wild-type, p27Kip1/,
p130/, and p27Kip1/; p130/ mice were incubated with
optimal concentrations of anti-IgM, anti-CD40, IL-4, anti-IgM
and anti-CD40, anti-IgM and IL-4, IL-4 and anti-CD40, or
LPS. The results showed that, in most conditions, [3H]thymi-
dine incorporation in the B cells of p130/ mice is compara-
ble with that in wild-type cells. Higher levels of [3H]thymidine
incorporation occurred in the B cells of p27Kip1/ mice, which
was increased further in the doubly deficient B cells. The ma-
jority of the cells entered S phase between 44 and 72 h. It is
notable that there was a reduction in [3H]thymidine uptake at
72 h compared with that at 48 h by some of the B cells,
especially under strong mitogenic stimulatory conditions (e.g.,
LPS). This probably reflects the fact that the majority of the
cycling cells had already exited/traversed S phase at 72 h under
these conditions. The [3H]thymidine incorporation experi-
ments suggested that the B cells of p27Kip1/; p130/ doubly
deficient mice enter S phase more rapidly (measured ex vivo)
than the B cells of p27Kip1/ mice, which in turn are more
rapid than the B cells of wild-type and p130/ mice. It is also
notable that there was a small but significant number of B cells
of p27Kip1/; p130/ mice entering the cell cycle in the
absence of mitogenic stimulation, suggesting that normal
G03G13S-phase controls are abrogated.
DISCUSSION
It is believed that the CKI p27Kip1 sets stoichiometric inhib-
itory thresholds for proliferation and thereby prevents prema-
ture or inappropriate cell cycle entry. Mice deficient for
p27Kip1 are recognized to develop hyperplasia in multiple cell
types and lineages (15, 23, 32). In particular, the increase in the
cellularity and weight of hematopoietic organs, such as the
thymus and spleen, far exceeds the general increase in body
weight, suggesting that p27Kip1 is a hematopoietic tissue-spe-
cific regulator of hematopoietic cell cycle entry and prolifera-
tion. Indeed, p27Kip1 provides the major inhibitory control
on CDK2 activity in the majority of hematopoietic cells (14,
16, 40).
The lack of overt proliferative phenotypes in the major he-
matopoietic organs of the p27Kip1/ mice also indicates func-
tional redundancy, and compensation exists to prevent excess
uncontrolled proliferation (15, 23, 32). Previous studies have
shown that the deletion of p27Kip1 selectively induced the pro-
liferation of hematopoietic progenitor cells in the spleen (15).
Our study demonstrated that the knockout of p27Kip1 also
enhanced the cell cycle entry and proliferation of more mature
B cells in response to mitogenic stimulations. Previous data
demonstrated that p27Kip1 deletion leads to enhanced mitogen
responsiveness in T cells in vitro (20, 30). We showed that this
is also true for B cells. In this report, we provided both mo-
lecular and genetic evidence for the concept that p130 func-
tions to compensate for the absence of p27Kip1 in binding to
and inhibiting CDK2 and that p130 is a bona fide CKI in vivo.
Our immunoprecipitation and immunodepletion results indi-
cate that the pRB-related protein p130 can compensate for the
absence of p27Kip1 in binding to and repressing CDK2 in
spleen and thymus. This is further supported by the hyperpro-
liferative effects observed in the splenocytes of p27Kip1 and
p130 double-mutant mice compared with those seen in their
p27Kip1/ single-mutant counterparts. Our results also indi-
cate that the compensatory mechanism does not involve the
classical CKIs p21Cip1 and p57Kip2 because there was no de-
tectable amount of p21Cip1 or p57Kip2 binding to the inactive
CDK2 in the hematopoietic cells of either quiescent wild-type
or p27Kip1/ mice (data not shown). Moreover, while p21Cip1
expression levels were not elevated in the cells of p27Kip1/
mice, p57Kip2 is not expressed at significant levels. Indeed,
p21Cip1 has also been reported to have a positive rather than
negative role on hematopoietic cell proliferation. The en-
hanced cell proliferation status and hyperphosphorylation of
pRB in hematopoietic cells have been shown to be associated
with an increase in p21Cip1 expression level (41). Active CDK
complexes containing p21Cip1 have been detected, and it has
been suggested that p21Cip1 may stabilize such complexes.
Therefore, p21Cip1 may have a role independent of growth
arrest in hematopoietic cells (18). Both p27Kip1 and p130 have
broad antiproliferative effects on a variety of cell types and
tissues outside the hematopoietic system. To eliminate the
possibility of the p27Kip1- and p130-dependent environment
FIG. 7. Expression of cell-cycle regulatory proteins and CDK2 ki-
nase analysis in purified B220, CD3, Ter-119, and Gr1 spleno-
cytes. Nucleated splenocytes were harvested from wild-type,
p27Kip1/, p130/, and p27Kip1/; p130/ mice and sorted accord-
ing to cell surface markers using immunomagnetic microbeads against
B220 (B cells), CD3 (T cells), Gr1 (monocytes plus macrophages), and
Ter-119 (erythroid progenitors). (A) Lysates (30 g) prepared from
purified B220, CD3, Ter-119, and Gr1 splenocytes were used for
Western blot analysis for cell cycle regulatory proteins, including
CDK2, p27Kip1, pRB, and p130. The activity of CDK2 was determined
using phosphospecific anti-pRB antibodies raised against CDK2-spe-
cific sites. Actin was used as a loading control. (B) Splenic cell lysates
of wild-type and knockout mice immunoprecipitated (IP) with anti-
bodies against CDK2 were analyzed for cyclin-dependent kinase ac-
tivity in an in vitro kinase assay using recombinant pRB as a substrate.
The 32P-labeled pRB was then separated by gel electrophoresis, trans-
ferred onto a nitrocellulose membrane, and analyzed by exposure to
autoradiographic film.
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having an influence on hematopoietic development in these
mice, we used B cells as a model system to test their prolifer-
ative potential in vitro. The finding that the B cells of
p27Kip1/; p130/ doubly deficient mice are hypersensitive
to mitogenic stimulations in vitro supports the idea that the
hyperproliferation of splenocytes is not solely a result of the
influence of their environment in vivo.
Previous studies have shown that a unique domain within
the spacer region of p130 is essential for binding to and inhib-
iting CDK2 (12, 44). Although the amino acid sequence of this
FIG. 8. Immunoprecipitation analysis of CDK2, CDK4, CDK6, p27Kip1, and p130 complexes in wild-type, p27Kip1/, p130/, and p27Kip1/;
p130/ mice. Thymic and splenic cell lysates of wild-type and knockout mice were immunoprecipitated (IP) with antibodies against (A) CDK2,
(B) CDK4, (C) CDK6, (D) p130, or (E) p27Kip1. The immunoprecipitated CDK2 complexes were analyzed by Western blotting for p27Kip1, p130,
and p107. The immunoprecipitated CDK4 and CDK6 complexes were analyzed by Western blotting for p27Kip1 and p130 and the p27Kip1 and p130
complexes for CDK2. The asterisk denotes a spoilt lane, and the immunoprecipitation analysis of CDK2 was repeated (shown underneath).
FIG. 9. Immunodepletion analysis of p27Kip1 and p130 complexes in thymi and spleens of wild-type, p27Kip1/, p130/, and p27Kip1/;
p130/ mice. Whole-cell extracts were immunodepleted (ID) with three rounds of immunoprecipitation using specific antibodies against
(A) p27Kip1 or (B) p130. The resultant supernatants were immunoblotted for CDK2 and p27Kip1 or p130.
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domain is not shared with the pRB-related p107 pocket pro-
tein, p107 has also been shown to be able to associate with and
repress CDK2 through another p21Cip1-like motif located at
the spacer region (2, 44, 47). Another second cyclin-binding
site has also mapped to the N-terminal portions of p107 and
p130 (2, 44). This N-terminal domain is capable of inhibiting
cyclin-cdk2 complexes. It is therefore plausible that p107 can
also functionally substitute for the absence of p27Kip1 and p130
in the p27Kip1 and p130 doubly deficient cells. In agreement
with this idea, our data demonstrate that p107, like p130, can
also bind to CDK2 in both spleen and thymus. Interestingly, in
particular in the thymus, the amount of p107 binding to CDK2
increases when p27Kip1 is absent, indicating that p107 might
also functionally compensate for p27Kip1 in repressing CDK2.
This compensatory mechanism can help to explain for the lack
of a significant proliferative phenotype in the p130 and p27Kip1
doubly deficient thymocytes and, possibly, for the absence of
even more severe disorders in the splenocytes. In the thymo-
cytes, the expression level of p107 is high compared with that
in the splenocytes, thus allowing p107 to play a more promi-
nent role than that of p130 in inhibiting CDK2 activity. This
may explain the lack of excessive thymocyte proliferation when
both p130 and p27Kip1 are lost and is supported by the finding
that high levels of p107 are associated with CDK2 in the thy-
mus but not the spleen. The high intrinsic levels of CDK2
could also potentially exacerbate the situation in the thymo-
cytes. Indeed, functional compensation between pRB family
proteins has previously been documented in vivo, but it has
mostly centered on their roles in repressing E2F activity (6, 7,
11, 36). These findings also suggest that the ability of p130 to
compensate for the absence of p27Kip1 is tissue and cell type
specific, depending on the relative intrinsic cellular abundance
of p130 and p107.
It is notable that the hyperproliferative phenotype of p27Kip1
and p130 double deletion affects only splenic cells and not
thymocytes. This can be explained by the fact that the majority
FIG. 10. [3H]thymidine incorporation assay. Small, dense B cells were harvested from the spleens of either wild-type, p27Kip1/, p130/, or
p27Kip1/; p130/ mice and incubated with IL-4, anti ()-CD40, anti-IgM, IL-4anti-CD40, IL-4anti-IgM, anti-IgManti-CD40, LPS, or
medium only for 0 (black bars), 24 (gray bars), 48 (hatched bars), and 72 (white bars) h. The cells were pulsed with [3H]thymidine for 4 h and
harvested, and radioactivity was quantified. The [3H]thymidine uptake was plotted against time, and the result is representative of three individual
sets of experiments. Each time point is derived from a triplicate set of results (mean 	 SD [error bars]; n  3). Due to the differences in kinetics
of cell cycle entry between different treatments, Student t tests were performed on the maximum [3H]thymidine uptake points between the DKO
samples and the WT, p27Kip1/, or p130/ samples. There is a statistically significant difference in [3H]thymidine uptake between the DKO group
and the other genotypes (P  0.01 in response to IL-4, anti-IgM, IL-4anti-CD40, IL-4anti-IgM, anti-IgManti-CD40, LPS, and medium only
but not to anti-CD40). NS, not significant. , statistically significant (P  0.01).
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(95%) of cells in the thymus are of one cell type, CD4 or
CD8 T cells, and this one cell type contributes significantly to
the phenotype of the total thymic cell population. Conversely,
the fact that hyperproliferative effects of p27Kip1 and p130
deletion affect multiple splenic cell types (i.e., B and T lym-
phocytes, erythroid cells, monocytes, and macrophages) illus-
trates that this compensatory mechanism that exists between
p27Kip1 and p130 is common in many different hematopoietic
cells. Our data therefore suggest that cell types, such as spleno-
cytes, that intrinsically express low amounts of p107 are largely
dependent on p130 for the regulation of the CDK2 activity in
the absence of p27Kip1. It is also notable that the deletion of
both p27Kip1 and p130 has a more significant effect on the
proliferation of the myeloid populations (erythroid cells,
monocytes, and macrophages) than on the lymphoid cells (B
and T cells). This probably reflects that the erythroid cells,
monocytes, and macrophages or their progenitors are more
dependent on p27Kip1 and p130 in their cell cycle entry control
compared with the splenic T and B cells, and this can be
governed by the relative expression levels of different CKIs in
each cell type.
The biological significance of p27Kip1 and p130 having
overlapping functions is unclear. Our previous data sug-
gested that the repression of CDK2 activity by p27Kip1 is
required for the G1 arrest induced by the inhibition of the
phosphoinositide 3-kinase (PI3K) pathway (10). We also
showed that the reason why p27Kip1/ MEFs still entered
cell cycle arrest after treatment with the PI3K inhibitor
LY294002 is due to a compensatory mechanism by which
p130 functionally substitutes for p27Kip1 deficiency (10).
These results indicate that both p27Kip1 and p130 are down-
stream effectors of the PI3K pathway. In support of this
indication, we have recently demonstrated that both p27Kip1
and p130 are direct gene targets of the FOXO subfamily of
transcription factors (13, 24). The inhibition of the PI3K
pathway induces a cell cycle arrest mediated by p27Kip1 and
p130. The fact that both p27Kip1 and p130 function down-
stream of the same regulatory pathway may well be impor-
tant. One possible explanation is that this compensatory
mechanism exists to ensure that the cell cycle regulatory
function of the PI3K pathway is intact even if one effector
becomes inactivated. This compensatory mechanism may
provide an essential proliferation control in settings where
p27Kip1 is not expressed at normal levels, as is the case in
many human tumors and hyperplasia. The cooperation be-
tween these two cell cycle inhibitors is further supported by
a recent study from another group of researchers who also
generated mice lacking p130 and p27Kip1 and showed that
p130 and p27Kip1 cooperate to control the mobilization of
angiogenic progenitors from bone marrow (42).
In summary, we show that p130 and p27Kip1 cooperate to
regulate hematopoietic cell proliferation. Our data also indi-
cate that p130 is a bona fide cyclin-dependent kinase inhibitor
in vivo and functions to compensate for the absence of p27Kip1
to inhibit CDK activity. Ultimately, the generation of mice
deficient for p27Kip1, p130, and/or p107 will be required to
understand the compensatory mechanisms that exist to control
cell cycle entry and progression in hematopoietic cells in dif-
ferent organs in vivo.
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